Quantcast
Environmental News for a Healthier Planet and Life

First Trial of Moderna's Coronavirus Vaccine Produces Immune Response in All Participants

Health + Wellness
First Trial of Moderna's Coronavirus Vaccine Produces Immune Response in All Participants
The results from Moderna's Phase 1 coronavirus vaccine show it is safe and effective so far. Jakub Porzycki / NurPhoto via Getty Images

Results from the Phase 1 trial of Cambridge, Massachusetts biotech firm Moderna's coronavirus vaccine show it is safe and produces an immune response.


The preliminary report of the trial, published in The New England Journal of Medicine Tuesday, reveals that all 45 participants developed so-called neutralizing antibodies that bind to the virus and stop it from attacking other cells. They developed these antibodies at levels comparable to the upper half of COVID-19 survivors.

"The good news is that this vaccine induced antibodies," director of the National Institute of Allergy and Infectious Diseases Anthony Fauci told Bloomberg News. "Not just any kind of antibodies, but neutralizing antibodies."

Public health experts agree that a vaccine is necessary to return life to normal in the wake of a pandemic that has infected millions and killed almost 575,000, according to Reuters. More than one vaccine will probably be required, because it will be difficult for any one company to produce the billions of doses needed, The New York Times pointed out.

"None of us are safe unless all of us are safe," Columbia University virologist Dr. Angela Rasmussen told The New York Times. "It's not just us. It's everybody in the world."

The Moderna vaccine candidate was the first to be tested on human subjects, and Tuesday's published paper confirms the positive results reported by the company in May.

In the trial, 45 people aged 18 to 55 received two doses of the vaccine 28 days apart, according to Reuters. They received doses of either 25, 100 or 250 micrograms.

More than half of the people who received the middle dose experienced side effects like fatigue, chills, headache and muscle pain and 40 percent of them developed a fever after the second dose, according to Bloomberg. Three of the 14 people who received the highest dose suffered severe side effects, but the company has decided to stop testing that dose.

Fauci said the side-effects were normal and not a cause for concern, but other experts disagreed.

"Man, that is a lot of adverse events," Tony Moody, a doctor and researcher at the Duke Human Vaccine Institute, told Bloomberg.

However, Moody also said the amount of antibodies produced was "really encouraging."

The vaccine's safety and effectiveness cannot truly be assessed until a larger study is conducted, University of Pennsylvania infectious disease expert Dr. Paul Offit told The New York Times.

"[I]t's reading the tea leaves," he said. "You just don't know anything until you do a Phase 3 trial."

Moderna's Phase 3 trial is set to begin July 27 with 30,000 participants, half of whom will receive a placebo. It should be finished by late October, but it is unclear if the company will know if the vaccine works by then, since it has to prove participants are less likely to contract the virus. If the vaccine does work, Moderna said it would be able to manufacture between 500 million and one billion of the 100-microgram doses a year starting in 2021, Reuters reported.

A replica of a titanosaur. AIZAR RALDES / AFP via Getty Images

New fossils uncovered in Argentina may belong to one of the largest animals to have walked on Earth.

Read More Show Less

EcoWatch Daily Newsletter

Trump's Affordable Clean Energy rule eliminated a provision mandating that utilities move away from coal. VisionsofAmerica /Joe Sohm / Getty Images

A federal court on Tuesday struck down the Trump administration's rollback of the Obama-era Clean Power Plan regulating greenhouse gas emissions from power plants.

Read More Show Less

Trending

A wild mink in Utah was the first wild animal in the U.S. found with COVID-19. Peter Trimming via Wikipedia, CC BY-SA

By Jonathan Runstadler and Kaitlin Sawatzki

Over the course of the COVID-19 pandemic, researchers have found coronavirus infections in pet cats and dogs and in multiple zoo animals, including big cats and gorillas. These infections have even happened when staff were using personal protective equipment.

Read More Show Less
A mass methane release could begin an irreversible path to full land-ice melt. NurPhoto / Contributor / Getty Images

By Peter Giger

The speed and scale of the response to COVID-19 by governments, businesses and individuals seems to provide hope that we can react to the climate change crisis in a similarly decisive manner - but history tells us that humans do not react to slow-moving and distant threats.

Read More Show Less
Doug Emhoff, U.S. Vice President-elect Kamala Harris, Jill Biden and President-elect Joe Biden wave as they arrive on the East Front of the U.S. Capitol for the inauguration on Jan. 20, 2021 in Washington, DC. Joe Raedle / Getty Images

By John R. Platt

The period of the 45th presidency will go down as dark days for the United States — not just for the violent insurgency and impeachment that capped off Donald Trump's four years in office, but for every regressive action that came before.

Read More Show Less